Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy R Sanhai

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 31, 2008
Working together to enhance the efficiency of medical product developmentWendy R Sanhai
Drug Discovery Today. Technologies|July 2, 2014
A critical path approach to advance nanoengineered medical productsWendy R Sanhai, Jack Spiegel, Mauro Ferrari
Anesthesiology|February 4, 2010
ACTION on the prevention of chronic pain after surgery: public-private partnerships, the future of analgesic drug developmentBob A Rappaport, Igor Cerny, Wendy R Sanhai
Nature Nanotechnology|July 26, 2008
Seven challenges for nanomedicineWendy R Sanhai, Jason H Sakamoto, Richard Canady, et al.
Drug Discovery Today. Technologies|July 2, 2014
Drug eluting stents and the critical path initiative: Evolving paradigms for safety evaluationWendy R Sanhai, Norman Stockbridge, Robert P Fiorentino, et al.
The Lancet. Infectious Diseases|January 22, 2013
A comprehensive regulatory framework to address the unmet need for new antibacterial treatmentsJohn H Rex, Barry I Eisenstein, Jeff Alder, et al.
The Lancet. Infectious Diseases|September 28, 2013
Addressing the need for new antibacterials--authors' replyJohn H Rex, Barry I Eisenstein, Jeff Alder, et al.
Nature Reviews. Drug Discovery|July 2, 2010
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectivesHarald Hampel, Richard Frank, Karl Broich, et al.
Pain|December 15, 2010
Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTIONRobert H Dworkin, Dennis C Turk, Nathaniel P Katz, et al.
American Heart Journal|April 21, 2009
Assessing proarrhythmic potential of drugs when optimal studies are infeasibleEdwin P Rock, John Finkle, Howard J Fingert, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 31, 2008
Working together to enhance the efficiency of medical product developmentWendy R Sanhai
Drug Discovery Today. Technologies|July 2, 2014
A critical path approach to advance nanoengineered medical productsWendy R Sanhai, Jack Spiegel, Mauro Ferrari
Anesthesiology|February 4, 2010
ACTION on the prevention of chronic pain after surgery: public-private partnerships, the future of analgesic drug developmentBob A Rappaport, Igor Cerny, Wendy R Sanhai
Nature Nanotechnology|July 26, 2008
Seven challenges for nanomedicineWendy R Sanhai, Jason H Sakamoto, Richard Canady, et al.
Drug Discovery Today. Technologies|July 2, 2014
Drug eluting stents and the critical path initiative: Evolving paradigms for safety evaluationWendy R Sanhai, Norman Stockbridge, Robert P Fiorentino, et al.
The Lancet. Infectious Diseases|January 22, 2013
A comprehensive regulatory framework to address the unmet need for new antibacterial treatmentsJohn H Rex, Barry I Eisenstein, Jeff Alder, et al.
The Lancet. Infectious Diseases|September 28, 2013
Addressing the need for new antibacterials--authors' replyJohn H Rex, Barry I Eisenstein, Jeff Alder, et al.
Nature Reviews. Drug Discovery|July 2, 2010
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectivesHarald Hampel, Richard Frank, Karl Broich, et al.
Pain|December 15, 2010
Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTIONRobert H Dworkin, Dennis C Turk, Nathaniel P Katz, et al.
American Heart Journal|April 21, 2009
Assessing proarrhythmic potential of drugs when optimal studies are infeasibleEdwin P Rock, John Finkle, Howard J Fingert, et al.
Pageof 1